BRPI0820980A2 - Composições e métodos para detecção de tiabs - Google Patents

Composições e métodos para detecção de tiabs

Info

Publication number
BRPI0820980A2
BRPI0820980A2 BRPI0820980-4A BRPI0820980A BRPI0820980A2 BR PI0820980 A2 BRPI0820980 A2 BR PI0820980A2 BR PI0820980 A BRPI0820980 A BR PI0820980A BR PI0820980 A2 BRPI0820980 A2 BR PI0820980A2
Authority
BR
Brazil
Prior art keywords
thiab
compositions
detection
methods
thiab detection
Prior art date
Application number
BRPI0820980-4A
Other languages
English (en)
Inventor
Bernard Bihain
Virginie Ogier
Marie Brulliard
Original Assignee
Transmedi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transmedi Sa filed Critical Transmedi Sa
Publication of BRPI0820980A2 publication Critical patent/BRPI0820980A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0820980-4A 2007-12-14 2008-12-15 Composições e métodos para detecção de tiabs BRPI0820980A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301680A EP2071334A1 (en) 2007-12-14 2007-12-14 Compositions and methods of detecting TIABS
PCT/IB2008/003836 WO2009077864A2 (en) 2007-12-14 2008-12-15 Compositions and methods of detecting tiabs

Publications (1)

Publication Number Publication Date
BRPI0820980A2 true BRPI0820980A2 (pt) 2015-06-23

Family

ID=39473819

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820980-4A BRPI0820980A2 (pt) 2007-12-14 2008-12-15 Composições e métodos para detecção de tiabs

Country Status (14)

Country Link
US (1) US9068988B2 (pt)
EP (2) EP2071334A1 (pt)
JP (1) JP6076581B2 (pt)
KR (1) KR101595305B1 (pt)
CN (1) CN101971026B (pt)
AU (1) AU2008337238B2 (pt)
BR (1) BRPI0820980A2 (pt)
CA (1) CA2709130A1 (pt)
EA (1) EA018597B1 (pt)
IL (1) IL206225A0 (pt)
MX (1) MX2010006484A (pt)
NZ (1) NZ586737A (pt)
WO (1) WO2009077864A2 (pt)
ZA (1) ZA201004914B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US9709565B2 (en) * 2010-04-21 2017-07-18 Memed Diagnostics Ltd. Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
JP5640774B2 (ja) 2011-01-28 2014-12-17 富士通株式会社 情報照合装置、情報照合方法および情報照合プログラム
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
KR102102239B1 (ko) 2012-01-09 2020-04-21 에이디씨 테라퓨틱스 에스에이 유방암을 치료하기 위한 방법
CN108802385B (zh) 2012-02-09 2022-02-08 米密德诊断学有限公司 用于诊断感染的标记和决定因素和其使用方法
WO2013165262A1 (en) * 2012-04-30 2013-11-07 Auckland Uniservices Limited Peptides, constructs and uses therefor
BR112017002884A2 (pt) 2014-08-14 2018-01-30 Memed Diagnostics Ltd ?análise computacional de dados biológicos por meio do uso de variedade e hiperplano?
US20170234873A1 (en) 2014-10-14 2017-08-17 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections in non-human subjects and methods of use thereof
CN107209184B (zh) 2014-12-11 2020-04-24 米密德诊断学有限公司 用于诊断多种感染的标记组合及其使用方法
EP3423590A4 (en) 2016-03-03 2020-02-26 Memed Diagnostics Ltd. DETERMINANTS OF RNA TO DIFFERENTIATE BACTERIAL VIRAL INFECTIONS
IL294121B2 (en) 2016-03-03 2023-09-01 Memed Diagnostics Ltd An RNA test to diagnose the type of infection
JP6899890B2 (ja) * 2016-03-18 2021-07-07 ジェンクリＧｅｎｃｌｉｓ アレルギーの分子起源
JP2019513373A (ja) * 2016-03-31 2019-05-30 ネオン セラピューティクス， インコーポレイテッド ネオ抗原およびその使用方法
WO2018011796A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Early diagnosis of infections
CA3027341A1 (en) 2016-07-10 2018-01-18 Memed Diagnostics Ltd. Protein signatures for distinguishing between bacterial and viral infections
US11385241B2 (en) 2016-09-29 2022-07-12 Memed Diagnostics Ltd. Methods of prognosis and treatment
WO2018060999A1 (en) 2016-09-29 2018-04-05 Memed Diagnostics Ltd. Methods of risk assessment and disease classification
RU2674994C2 (ru) * 2016-12-29 2018-12-14 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ определения маркеров наличия опухолевых т-лимфобластов
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
US10209260B2 (en) 2017-07-05 2019-02-19 Memed Diagnostics Ltd. Signatures and determinants for diagnosing infections and methods of use thereof
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
JP7523358B2 (ja) * 2018-06-13 2024-07-26 アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ ムスカリン受容体ｍ３に対して阻害活性を有するペプチド
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
US20220349010A1 (en) * 2018-07-26 2022-11-03 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
KR102599650B1 (ko) * 2020-11-12 2023-11-08 서울대학교산학협력단 신규한 지질펩티드 화합물, 이의 생산 방법, 및 이의 용도
TW202241925A (zh) * 2021-01-15 2022-11-01 德商英麥提克生物技術股份有限公司 用於不同類型癌症免疫治療的ｈｌａ展示肽
EP4162948A1 (en) * 2021-10-05 2023-04-12 Genclis Transcription infidelity derived chimeric immunogens and uses thereof
CN114685609B (zh) * 2022-04-11 2023-04-14 东北农业大学 一种超短自组装抗菌肽fwr及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4347701A (en) * 2000-03-01 2001-09-12 Corixa Corp Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2009532664A (ja) * 2006-02-27 2009-09-10 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 癌の治療のためのノボペプチドの同定および使用
EP1887088A1 (en) 2006-07-20 2008-02-13 Transmedi SA Transcription infidelity, detection and uses thereof

Also Published As

Publication number Publication date
EA201070738A1 (ru) 2011-04-29
NZ586737A (en) 2014-08-29
KR20100124247A (ko) 2010-11-26
EP2235527A2 (en) 2010-10-06
JP2011505825A (ja) 2011-03-03
EA018597B1 (ru) 2013-09-30
HK1144319A1 (en) 2011-02-11
AU2008337238A1 (en) 2009-06-25
US20110097743A1 (en) 2011-04-28
MX2010006484A (es) 2010-09-10
US9068988B2 (en) 2015-06-30
WO2009077864A2 (en) 2009-06-25
WO2009077864A3 (en) 2009-08-13
CN101971026A (zh) 2011-02-09
CN101971026B (zh) 2016-05-04
JP6076581B2 (ja) 2017-02-15
IL206225A0 (en) 2010-12-30
CA2709130A1 (en) 2009-06-25
KR101595305B1 (ko) 2016-02-18
EP2235527B1 (en) 2015-06-24
ZA201004914B (en) 2011-04-28
EP2071334A1 (en) 2009-06-17
AU2008337238B2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
BRPI0820980A2 (pt) Composições e métodos para detecção de tiabs
PT2144998T (pt) Métodos e composições para vírus vivos atenuados
CY2017016I2 (el) Αναστολεις πρωτεασωματος
BRPI0912703A2 (pt) composições imuno-moduladoras e métodos para uso dessas
BRPI0918652A2 (pt) Composições farmacêuticas e métodos de libração relacionadas.
BRPI0909780A2 (pt) Composições e métodos para liberação de fármaco
BRPI0815725A2 (pt) Métodos para detecção de oligonucleotídeos
PT2356462T (pt) Composições e métodos anti-cxcr1
BRPI0920284A2 (pt) composição e método
BRPI0720604A2 (pt) Composição e método para detecção de desmineralização
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0815841A2 (pt) Métodos e composições para melhoramento de traços preferidos.
BRPI0806898A2 (pt) Inibidores de mek
EP2045016A4 (en) CRUSHING DEVICE
BRPI1012525A2 (pt) composições de nanopatículas isentas de príons e métodos para sua fabricação
HRP20170963T1 (hr) Modificirani saharidi
BRPI0806964A2 (pt) Combinações de agonístico beta-2-adrenoceptor e benzotiazolona
EP2101179A4 (en) ANALYSIS DEVICE
BRPI0810926A2 (pt) Antagonista de crig
BRPI0814876A2 (pt) Análogos de pirona fosforilados e métodos
BRPI0813922A2 (pt) composições de inibição de influenza e métodos.
EP2049032A4 (en) IMPROVED IMPINGER
BRPI0809678A2 (pt) Métodos
BRPI0912982A2 (pt) métodos, dispositivos, kits e composições para detectar nematódeos
BRPI0814748A2 (pt) Compostos de alditóis substituídos, composições e métodos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL